Skip to main content
. 2021 Nov 27;19:93. doi: 10.1186/s12959-021-00345-z

Table 2.

Studies about chemoprophylaxis in patients with spontaneous ICH

First author (year) Design N of pts Timing Prophylaxis Risk of VTE Risk of HE
/recurrent ICH

Boeer [40]

(1991)

Prospective 68 2 days vs. 4 days vs. 10 days UFH 5000 U q8h Reduction in number of PE in 2 days group (1 vs. 5 vs. 9) No significant difference

Wasay [41]

(2008)

Prospective 458 1–6 days UFH 2500-5000 U bid+GCS vs. GCS alone No significant difference No significant difference

Orken [42]

(2009)

Randomized trial 75 48 h Enoxaparin 4000 IU qd vs. GCS No significant difference No significant difference

Kiphuth [43]

(2009)

Retrospective 97 < 36 h Enoxaparin 4000 IU qd or dalteparin 2500 IU qd Not mentioned 0 at day 2

Faust [44]

(2017)

Retrospective 400 <48 h vs. ≥48 h Not mentioned 0.7% vs. 3.1% (P = 0.17) 5.6% vs. 5.0% (P = 0.80)

Ianosi [45]

(2019)

Retrospective 134 <48 h vs. ≥48 h Enoxaparin 2000 IU/4000 IU qd Not mentioned No significant difference

Kananeh [46]

(2021)

Retrospective 163 <24 h vs. ≥24 h UFH 5000 U q8h Not mentioned 3.4% vs. 6.7% (P = 0.49)

Qian [47]

(2021)

Randomized trial 139 24 h vs. 72 h Enoxaparin 2000 IU bid No significant difference No significant difference

N of pts number of patients; UFH unfractionated heparin; GCS graduated compression stockings; HE hematoma expansion